Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 955 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 955 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total value of $24,944.60. Following the sale, the insider owned 119,289 shares in the company, valued at approximately $3,115,828.68. This represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Monday, May 11th, Patrick Burnett sold 222 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $21.05, for a total value of $4,673.10.

Arcutis Biotherapeutics Stock Up 4.1%

ARQT opened at $27.10 on Thursday. Arcutis Biotherapeutics, Inc. has a fifty-two week low of $13.69 and a fifty-two week high of $31.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46. The firm’s fifty day moving average price is $25.87 and its two-hundred day moving average price is $24.68. The company has a market capitalization of $3.39 billion, a P/E ratio of -903.03 and a beta of 1.49.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The company had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. On average, analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current year.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong revenue growth and earnings beat: Second-quarter net product revenue reached $129.9 million, up 59% from the prior-year quarter and 23% sequentially. Adjusted earnings of $0.11 per share exceeded analyst estimates ranging from $0.06 to $0.09, compared with a $0.13 loss a year earlier. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Raised 2026 sales outlook: Arcutis increased its full-year net product sales guidance to $525 million–$540 million, signaling confidence in sustained demand for ZORYVE. The company also maintained positive operating cash flow during the quarter. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Expanded growth opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. The FDA also accepted an application for use in infants aged three to 24 months with mild-to-moderate atopic dermatitis, with a target decision date of February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Insider sales appear administrative: Three executives sold a combined 6,560 shares at approximately $26.12 per share. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting their significance as a bearish signal. SEC Insider Trading Filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Suvretta Capital Management LLC increased its stake in shares of Arcutis Biotherapeutics by 14.2% during the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after purchasing an additional 1,486,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Arcutis Biotherapeutics by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 7,253,936 shares of the company’s stock worth $210,654,000 after acquiring an additional 107,846 shares during the period. Polar Capital Holdings Plc increased its holdings in shares of Arcutis Biotherapeutics by 4.9% during the 4th quarter. Polar Capital Holdings Plc now owns 5,556,169 shares of the company’s stock worth $161,351,000 after acquiring an additional 257,415 shares during the last quarter. State Street Corp raised its stake in Arcutis Biotherapeutics by 18.2% in the 4th quarter. State Street Corp now owns 5,488,301 shares of the company’s stock valued at $159,380,000 after acquiring an additional 846,986 shares during the period. Finally, Morgan Stanley lifted its holdings in Arcutis Biotherapeutics by 1.5% during the 4th quarter. Morgan Stanley now owns 4,340,239 shares of the company’s stock valued at $126,041,000 after purchasing an additional 63,845 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ARQT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.